SAN
FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) management is scheduled to present at
the upcoming H.C. Wainwright 2nd Annual Autoimmune &
Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
The presentation and Q&A session will be accessible via a
webcast through a link posted on the Investor Events section of the
Nektar website:
https://ir.nektar.com/events-and-presentations/events. This webcast
will be available for replay until April 28,
2024.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology
company focused on developing treatments that address the
underlying immunological dysfunction in autoimmune and
chronic inflammatory diseases. Nektar's lead product
candidate, rezpegaldesleukin (REZPEG, or
NKTR-358), is a novel, first-in-class regulatory T
cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic
dermatitis and one in alopecia areata. Other
pipeline programs include two preclinical candidates, a PEG-colony
stimulating factor protein engineered to selectively modulate
resolution processes of inflammation and NKTR-0165, a bivalent
tumor necrosis factor receptor type II agonist
antibody. Nektar, together with various
partners, is also evaluating NKTR-255, an investigational IL-15
receptor agonist designed to boost the immune system's
natural ability to fight cancer, in several ongoing clinical
trials. Nektar is headquartered in San Francisco, California. For further
information, visit www.nektar.com and follow us on
LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar
Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212)
600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-the-hc-wainwright-2nd-annual-autoimmune--inflammatory-disease-virtual-conference-302097317.html
SOURCE Nektar Therapeutics